Abstract
PTH (teriparatide) is used in the treatment of osteoporosis, and can sometimes cause transient hypercalcemia, but to date there have been no reports of persistent hypercalcemia and hypophosphatemia resulting from its use. We describe a case with marked hypophosphatemia and hypercalcemia associated with the use of teriparatide. The patient was a 49-year-old woman who was followed up for acute intermittent porphyria and glucocorticoid-induced osteoporosis (following administration of prednisolone at 22.5 mg/day), and presented with unexplained fracture of the left tibia, for which treatment with teriparatide at 20 μg/day was started. Two weeks after treatment with teriparatide, the patient developed hypophosphatemia, hypercalcemia, hyperalkaline phosphatasemia, low TmP/GFR, FEca, BAP, and urinary NT×, with low intact PTH. These changes were considered to be related to teriparatide. Cessation of teriparatide treatment resulted in normalization of all parameters at 10 weeks (serum P 3.6 mg/dl, corrected Ca 8.8 mg/dl, ALP 273 IU/l, intact PTH 63 pg/ml). The observed abnormalities were considered to be in part related to acute intermittent porphyria, which is known to delay hepatic teriparatide clearance, with subsequent delay of PTH action despite its intermittent use, resulting in hypercalcemia and hypophosphatemia.
References
Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzi P, Klaushofter K (2003) Alendronate increases the degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185–191
Hernandez C, Beaupre GS, Marcus R, Carter DR (2001) A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29:511–516
Likuni N, Hamaya E, Nihojima S, Yokoyama S, Goto W, Taketsuna M, Miyauchi A, Sowa H (2012) Safety and effectiveness profile of raloxifene in long-term, prospective postmarketing surveillance. J Bone Miner Metab 30:674–682
Gowen M, Stroup GB, Dodds RA (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595–1604
Steddon SJ, Cunningham J (2005) Calcimimetics and calcilytics fooling the calcium receptor. Lancet 365:2237–2239
Chavassieux P, Asser Karsdal M, Segovia-Silvestre T, Chapurlat R, Boivin G, Delmas PD (2008) Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 23:1076–1083
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853
Quattrocchi E, Kourlas H (2004) Teriparatide: a review. Clin Ther 26:841–854
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ishi-shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–733
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17
Ryder KM, Tanner SB, Carbone L, Williams JE, Taylor HM, Bush A, Pintea V, Watsky MA (2010) Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals woth osteoporosis. J Bone Miner Metab 28:233–239
Miller PD, Bilezilian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R (2007) Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 92:3535–3541
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226
Karatoprak C, Kayatas K, Kilicaslan H, Yolbas S, Yazimci NA, Gumuskemer T, Demirtunc R (2012) Severe hypercalcemia due to teriparatide. Indian J Pharmacol 44:270–271
Fujita T, Baba H, Fukami T, Imai Y, Yoshimoto Y, Watanabe S, Katsuragi S, Takahara M (1984) Mechanism of degradation of N-terminal fragment of human parathyroid hormone (hPTH 1–34). Jpn J Bone Min Metab 2:142–153
EI Ouahabi H, Do Cao C, Janicki E, Mulliez E, Ajdi F, Wemwau JL (2011) Hepatic and cutaneous affections induced by antithyroid drugs revealing haemochromatosis and porphyria cutanea tarda. Presse Med 40:319–323
Conflict of interest
Dr. Tanaka and Dr. Okada have received consulting fees, speaking fees, and/or honoraria from Eli Lilly.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hajime, M., Okada, Y., Mori, H. et al. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab 32, 601–604 (2014). https://doi.org/10.1007/s00774-014-0564-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-014-0564-z